10. Drug allergy

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 2 SUPPL. 2, 2003, Pages

  Gruchalla, Rebecca S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Allergic drug reaction; Antimicrobial drugs; Desensitization; Graded challenge; Hapten hypothesis; Hypersensitivity syndrome; Penicillins; Skin testing

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; AMPRENAVIR; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; BIOLOGICAL RESPONSE MODIFIER; BRINZOLAMIDE; BUMETANIDE; CAPTOPRIL; CELECOXIB; CEPHALOSPORIN DERIVATIVE; CHLOROTHIAZIDE; CHLORPROPAMIDE; CHLORTALIDONE; DORZOLAMIDE; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; HEPARIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROTAMINE; ROFECOXIB; SULFONAMIDE; UNINDEXED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHOSPASM; DESENSITIZATION; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSPNEA; EOSINOPHILIA; ERYTHEMA; FEVER; FLUSHING; HEART DISEASE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNITY; LIVER DISEASE; LYMPHADENOPATHY; NEUTROPENIA; PAPULAR SKIN DISEASE; PATHOGENESIS; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROVOCATION TEST; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN NECROSIS; SKIN TEST; THROMBOCYTOPENIA; THROMBOSIS; TINNITUS; URTICARIA;

EID: 0037328753     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.93     Document Type: Review

References (77)

1. World Health Organization. International drug monitoring: the role of the hospital. Geneva: The Organization; 1966.
2. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,238 consecutive inpatients, 1975 to 1982. JAMA 1986;256:3358-63.
3. Laxenaire M. Epidemiology of anesthetic anaphylactoid reactions: fourth multicenter survey (July 1994-December 1996). Ann Fr Anesth Reanim 1999;18:796-809.
4. Lenler-Petersen P, Hansen D, Andersen M, Sorensen H, Billie H. Drug-induced fatal anaphylactic shock in Denmark 1968-1990. Ugeskr Laeger 1996;158:3316-8.
5. Pumphrey R. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:1144-50.
6. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D. editor. Textbook of adverse drug reactions. New York: Oxford University Press; 1991. p. 18-45.
7. Borda I, Slone D, Jick H. Assessment of adverse reactions within a drug surveillance program. JAMA 1968;205:645-7.
8. Coombs R, Gell PG. Classification of a allergic reactions responsible for clinical hypersensitivity and disease. In: Gell P, Coombs RR, Lachman PJ, editors. Clinical aspects of immunology. Oxford, UK: Blackwell Scientific Publications; 1975. p. 761.
9. Naisbitt D, Williams D, Pirmohamed M, Kitteringham N, Park K. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Immunol 2001;1:317-25.
10. Idsoe O, Guthe T, Wilcox R, deWeck A. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull WHO 1968;38:159-88.
11. International Rheumatic Fever Group. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. Lancet 1991;337:1308-10.
12. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis. J Allergy Clin Immunol 1998;101(6 Pt 2):S465-528.
13. Neugut A, Ghatak A Miller R. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 2001;161:15-21.
14. Levine B. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic disease in man. N Engl J Med 1966;275:1115-25.
15. Levine B, Redmond A. Minor haptenic determinant-specific reagins of penicillin hypersensitivity in man. Int Arch Allergy Appl Immunol 1969;35:445-55.
16. Adkinson N, Thompson W, Maddrey W, Lichtenstein L. Routine use of penicillin skin testing on an inpatient service. N Engl J Med 1971;285:22-4.
17. Green G, Rosenblum R, Sweet L. Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the Penicillin Study Group of the American Academy of Allergy. J Allergy Clin Immunol 1977;60:339-45.
18. Sullivan T, Wedner H, Shatz G, Yecies L, Parker C. Skin testing to detect penicillin allergy. J Allergy Clin Immunol 1981;68:171-80.
19. Sogn D, Evans RE Shepherd G, Casale T, Condemi J Greenberger P, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992;52:1025-32.
20. Weiss M, Adkinson, NF, Jr. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988;18:515-40.
21. Parker C. Drug therapy. N Engl J Med 1975;292:511-4.
22. Gorevic P, Levine B. Desensitization of anaphylactic hypersensitivity specific for the penicilloate minor determinant of penicillin and carbencillin. J Allergy Clin Immunol 1981;68:267-72.
23. Baldo B. Penicillins and cephalosporins as allergens - structural aspects of recognition and cross-reactions. Clin Exp Allergy 1999;29:744-9.
24. Lin R. A perspective on penicillin allergy. Arch Intern Med 1992;152:930-7.
25. Kelkar P, Li J. Cephalosporin allergy. N Engl J Med 2001;345:804-9.
26. Anne S, Reisman R. Risk of administering cephalosporin antibiotics to patients with histories of penicillil allergy. Ann Allergy Asthma Immunol 1995;74:167-70.
27. Novalbos A, Sastre J, Cuesta J, De Las Heras M, Lluch-Bernal M, Bombin C, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001;31:438-43.
28. Bernstein I, Gruchalla R, Lee R, Nicklas R, Dykewicz M. Disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999;83:665-700.
29. Kearns GI. Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual sensitivity. J Pediatr 1994;125:805-11.
30. Gruchalla R. Acute drug desensitization. Clin Exp Allergy 1998;28:63-4.
31. Sullivan T. Drug allergy. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, editors. Allergy: principles and practice. St Louis: Mosby; 1993. p. 1726-46.
32. Patterson R, DeSwarte R, Greenberger P, Grammar L, Brown J, Choy A. Drug allergy and protocols for management of drug allergies. Providence (RI): Oceanside Publications; 1995. p. 1-27.
33. Cribb A, Spielberg S. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990;18:784-7.
34. Naisbitt D, Hough S, Gill H, Pirmohamed M, Kitteringham N, Park B. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126:1393-407.
35. Gruchalla R, Pesenko, RD, Do, TT, Skiest, DJ. Sulfonamide-induced reactions in patients with AIDS - the role of covalent protein haptenation. J Allergy Clin Immunol 1998;101:371-8.
36. Reilly T, Lash L, Doll M, Hein D, Woster P, Svensson C. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164-73.
37. Naisbitt D, Gordon S, Pirmohamed M, Burkhart C, Cribb A, Pichler W. et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T cell proliferation in vivo. Br J Pharmacol 2001;133:295-305.
38. Pichler W, Schnyder B, Zanni M, Hari Y, von Greyerz S. Role of T cells in drug allergies. Allergy 1998;53:225-32.
39. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen L, Pichler W. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000;106:1171-6.
40. Carrington D, Earl H, Sullivan T. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987;79:442-7.
41. Gruchalla R, Sullivan T. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazole poly-L-tyrosine. J Allergy Clin 1991;88:784-92.
42. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-Infected patients. J Allergy Clin Immunol 1994;93:1001-5.
43. Moreno J, Poblete R, Maggio C, Gagnon S, Fischl M. Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol 1995;74:140-6.
44. Palusci V, Kaul A, Lawrence R, Haines K, Kwittken P. Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children. Pediatr Infect Dis J 1996;15:456-60.
45. Caumes E, Guermonprez G, Lecomte C, Katlama C, Bricaire F. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997;133:465-9.
46. Rich J, Sullivan T, Greineder D, Kazanjian P. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997;79:409-14.
47. Demoly P, Messaad D, Sahla H, Fabre J, Faucherre V, Andre P, et al. Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients. J Allergy Clin Immunol 1998;102:1033-6.
48. Yoshizawa S, Yasuoka A, Kikuchi Y, Honda M, Gatanaga H. Tachikawa N. et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol 2000;85:241-4.
49. Allen J. Which medications to avoid in patients with sulfa allergy. Stockton (CA): Pharmacist's Letter and Prescriber's Letter; 2000.
50. Weiss ME, Adkinson NF Jr. Diagnostic testing for drug hypersensitivity. Immunol Allergy Clin North Am 1998;18:731-44.
51. Brandt M, Gruchalla R, Sullivan T. Skin testing and in vitro testing to detect IgE to antimicrobial drugs [abstract]. J Allergy Clin Immunol 1993;91:263.
52. Empedrad R, Earl H, Gruchalla R. Determination of nonirritating skin test concentrations of commonly used antimicrobial drugs [abstract]. J Allergy Clin Immunol 2000;105:803.
53. Shear N, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988;82:1826-32.
54. Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2001;1:293-8.
55. Knowles S, Shapiro L, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
56. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
57. Lorenz W, Reimann H, Schmal A, Dormann P, Schwarz B, Neugebauer E, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7.
58. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102-5.
59. Zanotti K, Rybicki L, Kennedy A, Belinson J, Webster K, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001;19:3126-9.
60. Broome C, Schiff R, Friedman H. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996;26:105-10.
61. Rose P, Fusco N, Fluellen L, Rodriguez M. Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. Int J Gynecol Cancer 1998;8:365-6.
62. Billet A, Carls A, Belber R, Sallan S. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992;70:201-6.
63. Woo M, Hak L, Storm M, Evans W, Sandlund J, Rivera G, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-33.
64. Zanotti K, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001;24:767-79.
65. Bonno M, Kawasaki H, Hori H, Umemoto M, Komada Y, Sakurai M. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 1998;101:571-2.
66. O'Dwyer P, King S, Fortner C, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986;4:1262-9.
67. Kellie S, Crist W, Pui C, Crone M, Fairclough D, Rodman J, et al. Hypersensitivity reactions to epiphodophyllotoxins in children with acute lymphoblastic leukemia. Cancer 1991;67:1070-5.
68. MacLean J, Moscicki R, Block K. Adverse reactions to heparin. Ann Allergy 1990;65:254-9.
69. Harenberg J, Huhle G, Wang L, Hoffmann U, Bayerl C, Kerowgan M. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy 1999;54:473-7.
70. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg 2001;27:47-53.
71. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001;67:268-9.
72. Pratt E, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001;18:515-6.
73. Wessbecher R, Kiehn M, Stoffel E, Moll I. Management of insulin allergy. Allergy 2001;56:919-20.
74. Dykewicz M, Kim H, Orfan N, Yoo T, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol 1994;93:117-25.
75. Zeltser R, Valle L, Tanck C. Holyst M, Bitchlin C, Gaspari A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept. Arch Dermatol 2001;137:893-9.
76. Stevenson, DD, Simon, RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
77. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice, vol 2. 5th ed. St Louis: Mosby; 1998. p. 1225-34.